Table 4.
Mean clinical chemistry parameters for 28 week repeated oral doses of E. kebericho decoction treated rats
| Parameter | Male | Female | P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| control | 150 mg/kg | 300 mg/kg | 600 mg/kg | Control | 150 mg/kg | 300 mg/kg | 600 mg/kg | ||
| AST (U/L) | 260.2 ± 30.06 | 288.3 ± 70.71 | 241.6 ± 76.59 | 173.5 ± 21.89 | 304.2 ± 256.1 | 190.6 ± 20.74 | 193.6 ± 29.08 | 301.6 ± 309.4 | 0.0559 /0.1173 |
| ALT (U/L) | 84.20 ± 7.73 | 80.75 ± 6.99 | 88.00 ± 14.37 | 64.20 ± 6.30 | 123.0 ± 128.3 | 70.40 ± 4.88 | 56.60 ± 7.16 | 83.80 ± 22.11 | 0.0036 */0.6072 |
| ALP (U/L) | 74.60 ± 20.26 | 71.25 ± 23.91 | 106.6 ± 56.20 | 131.3 ± 16.88 | 197.8 ± 126.4 | 52.20 ± 16.98 | 45.40 ± 46.41 | 83.20 ± 32.82 | 0.0162 */0.0577 |
| Creatinine (mg/dl) | 0.60 ± 0.07 | 0.52 ± 0.10 | 0.52 ± 0.16 | 0.30 ± 0.12 | 0.60 ± 0.07 | 0.52 ± 0.08 | 0.46 ± 0.05 | 0.42 ± 0.11 | 0.0077 */0.0005 ** |
| Urea (mg/dL) | 40.30 ± 2.94 | 42.00 ± 1.26 | 50.48 ± 6.58 | 41.50 ± 3.90 | 47.22 ± 6.14 | 48.30 ± 7.97 | 42.72 ± 5.02 | 43.88 ± 3.51 | 0.1288/0.5085 |
| Protein total (g/dl) | 5.90 ± 0.73 | 6.30 ± 0.74 | 6.32 ± 1.00 | 5.80 ± 0.63 | 7.06 ± 0.56 | 6.60 ± 1.40 | 6.48 ± 0.58 | 6.62 ± 0.43 | 0.1531 /0.9694 |
| Albumin (g/dl) | 3.20 ± 0.12 | 3.22 ± 0.17 | 3.14 ± 0.21 | 3.05 ± 0.10 | 3.56 ± 0.24 | 3.36 ± 0.15 | 3.38 ± 0.22 | 3.42 ± 0.228 | 0.0122*/0.6266 |
| Glucose (mg/dl) | 127.4 ± 42.51 | 178.8 ± 69.63 | 181.6 ± 64.31 | 124.8 ± 33.04 | 116.2 ± 17.71 | 193.0 ± 45.67 | 140.0 ± 31.16 | 188.6 ± 62.42 | 0.0457*/0.0581 |
| Bil-total (mg/dl) | 0.18 ± 0.04 | 0.38 ± 0.15 | 0.20 ± 0.0 | 0.28 ± 0.10 | 0.26 ± 0.05 | 0.16 ± 0.05 | 0.24 ± 0.09 | 0.34 ± 0.05 | 0.0036*/0.0644 |
| Bil-direct (mg/dl) | 0.10 ± 0.0 | 0.32 ± 0.10 | 0.14 ± 0.06 | 0.12 ± 0.05 | 0.14 ± 0.06 | 0.20 ± 0.07 | 0.14 ± 0.06 | 0.22 ± 0.11 | 0.0129*/0.0065** |
| TG (mg/dl) | 79.40 ± 20.19 | 79.50 ± 8.96 | 66.60 ± 20.19 | 51.25 ± 13.45 | 98.00 ± 41.43 | 75.20 ± 14.45 | 58.00 ± 17.56 | 62.00 ± 9.38 | 0.0338*/0.0042** |
| Cholesterol (mg/dl) | 33.60 ± 10.85 | 79.50 ± 16.76 | 65.60 ± 15.63 | 38.50 ± 3.70 | 84.60 ± 37.63 | 81.80 ± 29.78 | 81.20 ± 18.10 | 80.60 ± 12.52 | 0.0013*/0.2970 |
*Significant p-value when males and females are treated separately, **Significant p-value when males and females are grouped together: Where, ALP Alkaline phosphatase, ALT Alanine aminotransferase, AST Aspartate Aminotransferase, TG Triglycerides, Bil-total Bilirubin Total, Bil-direct Direct Bilirubin3.2.3. Post-hoc analysis result